ClinicalTrials.Veeva

Menu
T

Trial Management Associates, LLC | Wilmington, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

GED-0301
Relamorelin
Vonoprazan
Iron
PF-00489791
Obeticholic Acid
Daclatasvir
Ferric Carboxymaltose
TVB-2640
Diltiazem Hydrochloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 51 total trials

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its...

Active, not recruiting
COVID-19
Biological: mRNA-1273.222
Biological: mRNA-1283.222

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immun...

Active, not recruiting
Influenza
SARS-CoV-2
Biological: Investigational Influenza Vaccine 1
Biological: COVID-19 Vaccine 2

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent seve...

Active, not recruiting
COVID-19
Biological: NVX-CoV2601 (5μg)
Biological: NVX-CoV2601 (35μg)

This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity an...

Active, not recruiting
SARS-CoV-2 Infection
Biological: Intramuscular vaccine
Drug: Intramuscular injection

Trial sponsors

Moderna logo
Allergan logo
Exact Sciences Corporation logo
Celgene logo
Ironwood Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Phathom Pharmaceuticals logo
V
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems